Using an unextracted radioimmunoassay procedure for the assay of medroxyprogesterone acetate in serum, the apparent half-life for medroxyprogesterone acetate following IM administration of medroxyprogesterone acetate injectable suspension is approximately 50 days. Women who completed 6 years gained an average of 16.5 lb.

(1989): age, parity, ethnic group, and year of interview. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity. BMD should be evaluated when a woman needs to continue to use medroxyprogesterone acetate injectable suspension long-term. Both patients had high anti-PEG IgG antibody titers at or around the time of the hypersensitivity reactions. Medroxyprogesterone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).What is medroxyprogesterone acetate injectable suspension?How well does medroxyprogesterone acetate injectable suspension work?To make sure that you are not pregnant before you take medroxyprogesterone acetate injectable suspension, the first injection should be given only:Who should not use medroxyprogesterone acetate injectable suspension?What should I tell my healthcare provider before takingEspecially tell your healthcare provider if you take:Follow your healthcare provider's instructions about using a back-up method of birth control if you are taking medicines that may makemedroxyprogesterone acetate injectable suspension less effective. In a controlled, clinical study, adult women using medroxyprogesterone acetate injectable suspension for up to 5 years showed spine and hip BMD mean decreases of 5 to 6%, compared to no significant change in BMD in the control group. T3-uptake values may decrease.

Medroxyprogesterone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs). If you would like more information, talk with your healthcare provider.

(f)    Sulfobromophthalein and other liver function test values may be increased. A woman who is taking hormonal contraceptive should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.The use of medroxyprogesterone acetate injectable suspension may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. Mean Percent Change from Baseline in BMD in Adults by Skeletal Site and Cohort (5 Years of Treatment and 2 Years of Follow-Up) Use of medroxyprogesterone acetate injectable suspension was associated with a significant decline from baseline in BMD.A retrospective cohort study to assess the association between DMPA injection and the incidence of bone fractures was conducted in 312,395 female contraceptive users in the U.K. Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. The longer you use medroxyprogesterone acetate injectable suspension, the greater your loss of calcium from your bones. However, medroxyprogesterone acetate injectable suspension has not been causally associated with the induction of thrombotic or thromboembolic disorders.

See full prescribing information for complete boxed warningWomen who use medroxyprogesterone acetate injectable suspension may lose significant bone mineral density. The decline in BMD was more pronounced during the first two years of use, with smaller declines in subsequent years. Medroxyprogesterone acetate injectable suspension can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). Its metabolism primarily involves ring A and/or side-chain reduction, loss of the acetyl group, hydroxylation in the 2-, 6-, and 21- positions or a combination of these positions, resulting in more than 10 metabolites. Importantly, this study could not determine whether use of DMPA has an effect on fracture rate later in life.Medroxyprogesterone acetate injectable suspension, USP is supplied as follows:Stored at controlled room temperature 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Read this Patient Information carefully before you decide if medroxyprogesterone acetate injectable suspension is right for you. �8Xu��MU�����͇�H?�n�#�W���8�ٌåL$qf;��he��>q �D��M+l�'�8"-i���ֺ�%��1f���p�����:�~9�n9 �� ��\�~7��"_?��^o/��1���._]��_�٬�;��x쾜�_���^�v�r6�� ���q�x��r��û�|���j䝄Ï�������ջ����6z��d4��_2��~�X&;������������������z���Ev&��.-|J�B���{�Jw���}x{3�T����Bύ,?�����_ۙs�� As women continue using medroxyprogesterone acetate injectable suspension, fewer experience irregular bleeding and more experience amenorrhea. endstream endobj 983 0 obj <>stream

[Medroxyprogesterone acetate injectable suspension is not indicated before menarche. This information does not take the place of talking with your gynecologist or other healthcare provider who specializes in women's health.